Novo Nordisk Juggles MASH Milestone with Eli Lilly’s Triple-Agonist Surge
23.05.2026 - 20:01:11 | boerse-global.de
Novo Nordisk is fighting a battle on two fronts. As the Danish pharma giant prepares to unveil fresh data from its MASH pipeline this week, it must also contend with a stark reminder from Eli Lilly that the obesity throne is no longer secure. The stock, still nursing deep losses from its 2024 peak, offers a snapshot of a company in transition — leaning on its GLP-1 foundation while racing to prove there is more to its story than just weight loss.
MASH Data Takes Centre Stage in Barcelona
From May 27 to 30, Novo Nordisk will present new findings from the phase?3 ESSENCE trial at the EASL congress in Barcelona. The focus is Semaglutide 2.4?mg as a treatment for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease affecting an estimated 250?million people worldwide. Earlier results showed the drug significantly reduced liver inflammation and fibrosis. What is new this time are subgroup analyses that have rarely been explored: a dedicated evaluation for Japanese MASH patients and separate data on menopausal women.
The strategic logic is clear. According to the company’s internal data, more than one in three people with obesity also suffer from MASH. That makes the liver indication a natural adjacenty for Novo Nordisk’s existing GLP?1 platform — and a potential second revenue pillar beyond the crowded weight?loss market.
Lilly Raises the Bar with Retatrutide
But the competitive landscape is shifting fast. Eli Lilly’s triple agonist, Retatrutide, delivered an average weight loss of 28.3?% (roughly 32?kg) in a phase?3 trial involving 2,500 participants. Nearly 45?% of patients lost 30?% or more of their body weight, compared with just 2.2?% in the placebo group. The drug targets three receptors — GLP?1, GIP and glucagon — whereas Novo Nordisk’s Semaglutide imitates only GLP?1.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Lilly’s data cranks up the pressure on a market reportedly worth $100?billion by year?end. However, Retatrutide has not yet been approved; the earliest FDA decision is expected in 2027. Until then, Novo Nordisk has a window — albeit a narrowing one — to defend its turf.
Oral Wegovy Gains Traction
Novo Nordisk is betting heavily on the oral formulation of Wegovy, which has been on the market since January 2026. CEO Mike Doustdar reports double?digit growth rates for the pill, even as Lilly’s Foundayo launched in the US in April. In Europe, regulators have also given a positive opinion. The injectable version generated DKK?18.2?billion in first?quarter sales, up 12?% year?on?year, though that slightly missed expectations. The US new?prescription share still stands at 65?%. Doustdar calls it a “turning point situation.”
On the regulatory front, the CHMP recently recommended approval of the 25?mg Wegovy pill and a new single?use 7.2?mg pen. Management expects the first commercial launches outside the US in the second half of 2026, once the European Commission gives final approval. That would be another step toward reducing dependence on the fiercely competitive American weight?loss market.
Shares Claw Back, but the Gap Remains Wide
Novo Nordisk shares closed Friday at €38.74, up 1.25?% on the day and roughly 16?% over the past month. That recovery has lifted the stock more than 27?% from its March low of €30.48. Yet the picture over the past year is grim: the stock is down 36?%, and it trades nearly 45?% below its 52?week high of €70.13. The relative strength index stands at 47.3, neutral territory.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
A buyback programme is under way. Since May 6, Novo has been repurchasing B?shares under a current tranche of up to DKK?11.2?billion, valid until February 2027, within an annual framework of DKK?15?billion. The company has already bought back around DKK?4.17?billion worth of shares since February at an average price of roughly €35 per share. Despite this vote of confidence, the stock has not found a sustainable floor.
Institutional Interest Picks Up
Recent SEC filings reveal growing institutional appetite. Markel Group boosted its Novo Nordisk stake by just over 21?% in the fourth quarter, while Rathbones Group increased its position by 79?%. Whether this signals an early re?rating or simple opportunistic buying after the sell?off remains an open question. The next major catalyst will be the half?year results on August 5, 2026, where investors will look for evidence that the “turning point” is real.
Ad
Novo Nordisk Stock: New Analysis - 23 May
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
